Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Langenbeck's Archives of Surgery
Published in: Langenbeck's Archives of Surgery 1/2024

Open Access 01-12-2024 | Gastrointestinal Stromal Tumor | Research

The GIST of it all: management of gastrointestinal stromal tumors (GIST) from the first steps to tailored therapy. A bibliometric analysis

Authors: Julian Musa, Sarah M. Kochendoerfer, Franziska Willis, Christine Sauerteig, Jonathan M. Harnoss, Ingmar F. Rompen, Thomas G. P. Grünewald, Mohammed Al-Saeedi, Martin Schneider, Julian-C. Harnoss

Published in: Langenbeck's Archives of Surgery | Issue 1/2024

Login to get access

Abstract

Purpose

Improvement of patient care is associated with increasing publication numbers in biomedical research. However, such increasing numbers of publications make it challenging for physicians and scientists to screen and process the literature of their respective fields. In this study, we present a comprehensive bibliometric analysis of the evolution of gastrointestinal stromal tumor (GIST) research, analyzing the current state of the field and identifying key open questions going beyond the recent advantages for future studies to assess.

Methods

Using the Web of Science Core Collection, 5040 GIST-associated publications in the years 1984–2022 were identified and analyzed regarding key bibliometric variables using the Bibliometrix R package and VOSviewer software.

Results

GIST-associated publication numbers substantially increased over time, accentuated from year 2000 onwards, and being characterized by multinational collaborations. The main topic clusters comprise surgical management, tyrosine kinase inhibitor (TKI) development/treatment, diagnostic workup, and molecular pathophysiology. Within all main topic clusters, a significant progress is reflected by the literature over the years. This progress ranges from conventional open surgical techniques over minimally invasive, including robotic and endoscopic, resection techniques to increasing identification of specific functional genetic aberrations sensitizing for newly developed TKIs being extensively investigated in clinical studies and implemented in GIST treatment guidelines. However, especially in locally advanced, recurrent, and metastatic disease stages, surgery-related questions and certain specific questions concerning (further-line) TKI treatment resistance were infrequently addressed.

Conclusion

Increasing GIST-related publication numbers reflect a continuous progress in the major topic clusters of the GIST research field. Especially in advanced disease stages, questions related to the interplay between surgical approaches and TKI treatment sensitivity should be addressed in future studies.
Appendix
Available only for authorised users
Literature
1.
Blay JY, Kang YK, Nishida T, von Mehren M (2021) Gastrointestinal stromal tumours. Nat Rev Dis Primers 7(1):1–22CrossRef
2.
Casali PG, Blay JY, Abecassis N et al (2022) Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 33(1):20–33PubMedCrossRef
3.
Joensuu H, Vehtari A, Riihimäki J et al (2012) Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 13(3):265–274PubMedCrossRef
4.
Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279(5350):577–580ADSPubMedCrossRef
5.
Wozniak A, Rutkowski P, Piskorz A et al (2012) Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. Ann Oncol 23(2):353–360PubMedCrossRef
6.
Heinrich MC, Owzar K, Corless CL et al (2008) Correlation of kinase genotype and clinical outcome in the North American intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 26(33):5360–5367PubMedPubMedCentralCrossRef
7.
Debiec-Rychter M, Sciot R, Le Cesne A et al (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42(8):1093–1103PubMedCrossRef
8.
Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST) (2010) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 28(7):1247–1253CrossRef
9.
von Mehren M, Joensuu H (2018) Gastrointestinal stromal tumors. J Clin Oncol 36(2):136–143CrossRef
10.
Heinrich MC, Maki RG, Corless CL et al (2008) Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 26(33):5352–5359PubMedPubMedCentralCrossRef
11.
Evans EK, Gardino AK, Kim JL et al (2017) A precision therapy against cancers driven by KIT/PDGFRA mutations. Sci Transl Med 9(414):eaao1690PubMedCrossRef
12.
Smith BD, Kaufman MD, Lu WP et al (2019) Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer Cell 35(5):738-751.e9PubMedCrossRef
13.
Klug LR, Khosroyani HM, Kent JD, Heinrich MC (2022) New treatment strategies for advanced-stage gastrointestinal stromal tumours. Nat Rev Clin Oncol 19(5):328–341PubMedCrossRef
14.
Joensuu H, Eriksson M, Sundby Hall K et al (2020) Survival outcomes associated with 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: an analysis of a randomized clinical trial after 10-year follow-up. JAMA Oncol 6(8):1241–1246PubMedCrossRef
15.
Casali PG, Zalcberg J, Le Cesne A et al (2017) Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: long-term analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group intergroup phase III randomized trial on imatinib at two dose levels. J Clin Oncol 35(15):1713–1720PubMedCrossRef
16.
Aria M, Cuccurullo C (2017) bibliometrix: An R-tool for comprehensive science mapping analysis. J Informet 11(4):959–975CrossRef
17.
van Eck NJ, Waltman L (2010) Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics 84(2):523–538PubMedCrossRef
18.
Waltman L, van Eck NJ, Noyons ECM (2010) A unified approach to mapping and clustering of bibliometric networks. J Informetr 4(4):629–635CrossRef
19.
Perianes-Rodriguez A, Waltman L, van Eck NJ (2016) Constructing bibliometric networks: a comparison between full and fractional counting. J Informetr 10(4):1178–1195CrossRef
20.
Bornmann L, Haunschild R, Mutz R (2021) Growth rates of modern science: a latent piecewise growth curve approach to model publication numbers from established and new literature databases. Humanit Soc Sci Commun 8(1):1–15CrossRef
21.
Bornmann L, Mutz R (2015) Growth rates of modern science: a bibliometric analysis based on the number of publications and cited references. J Assoc Inf Sci Technol 66(11):2215–2222CrossRef
22.
Wang C, Gao Z, Shen K et al (2020) Safety and efficiency of endoscopic resection versus laparoscopic resection in gastric gastrointestinal stromal tumours: a systematic review and meta-analysis. Eur J Surg Oncol 46(4 Pt A):667–674PubMedCrossRef
23.
De Vogelaere K, Van Loo I, Peters O, Hoorens A, Haentjens P, Delvaux G (2012) Laparoscopic resection of gastric gastrointestinal stromal tumors (GIST) is safe and effective, irrespective of tumor size. Surg Endosc 26(8):2339–2345PubMedCrossRef
24.
Shi F, Li Y, Pan Y et al (2019) Clinical feasibility and safety of third space robotic and endoscopic cooperative surgery for gastric gastrointestinal stromal tumors dissection : a new surgical technique for treating gastric GISTs. Surg Endosc 33(12):4192–4200PubMedPubMedCentralCrossRef
25.
Ye X, Kang WM, Yu JC, Ma ZQ, Xue ZG (2017) Comparison of short- and long-term outcomes of laparoscopic vs open resection for gastric gastrointestinal stromal tumors. World J Gastroenterol 23(25):4595–4603PubMedPubMedCentralCrossRef
26.
Lin J, Huang C, Zheng C et al (2014) Laparoscopic versus open gastric resection for larger than 5 cm primary gastric gastrointestinal stromal tumors (GIST): a size-matched comparison. Surg Endosc 28(9):2577–2583PubMedCrossRef
27.
Ceccarelli G, Costa G, De Rosa M et al (2021) Minimally invasive approach to gastric GISTs: analysis of a multicenter robotic and laparoscopic experience with literature review. Cancers 13(17):4351PubMedPubMedCentralCrossRef
28.
Call JW, Wang Y, Montoya D, Scherzer NJ, Heinrich MC (2019) Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry. Clin Sarcoma Res 9(1):4PubMedPubMedCentralCrossRef
29.
Du CY, Zhou Y, Song C et al (2014) Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China. Eur J Cancer 50(10):1772–1778PubMedCrossRef
30.
Bauer S, Rutkowski P, Hohenberger P et al (2014) Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib – analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol 40(4):412–419PubMedCrossRef
31.
Mussi C, Ronellenfitsch U, Jakob J et al (2010) Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? Ann Oncol 21(2):403–408PubMedCrossRef
32.
Raut CP, Posner M, Desai J et al (2006) Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24(15):2325–2331PubMedCrossRef
33.
Wong JSM, Tan GHC, Quek R et al (2017) Is multivisceral resection in locally advanced gastrointestinal stromal tumours an acceptable strategy? ANZ J Surg 87(6):477–482PubMedCrossRef
34.
Racz JM, Sunil S, Abramowitz D et al (2015) Multivisceral resections for gastrointestinal stromal tumors: are the risks justifiable? Surg Oncol 24(1):54–59PubMedCrossRef
35.
Schurr P, Kohrs D, Reichelt U et al (2009) Repeated surgery improves survival in recurrent gastrointestinal stromal tumors: a retrospective analysis of 144 patients. Dig Surg 26(3):229–235PubMedCrossRef
36.
37.
38.
Ravegnini G, Urbini M, Simeon V et al (2019) An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor. Pharmacogenomics J 19(4):390–400PubMedCrossRef
39.
Rizzo A, Pantaleo MA, Astolfi A, Indio V, Nannini M (2021) The identity of PDGFRA D842V-mutant gastrointestinal stromal tumors (GIST). Cancers (Basel) 13(4):705PubMedCrossRef
40.
Heinrich MC, Jones RL, von Mehren M et al (2020) Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol 21(7):935–946PubMedCrossRef
41.
Nannini M, Nigro MC, Vincenzi B et al (2017) Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. Ther Adv Med Oncol 9(12):731–739PubMedPubMedCentralCrossRef
42.
van de Wal D, Elie M, Le Cesne A et al (2022) Health-related quality of life and side effects in gastrointestinal stromal tumor (GIST) patients treated with tyrosine kinase inhibitors: a systematic review of the literature. Cancers (Basel) 14(7):1832PubMedCrossRef
43.
Heinrich MC, George S, Zalcberg JR et al (2020) Quality of life (QoL) and self-reported function with ripretinib in ≥4th-line therapy for patients with gastrointestinal stromal tumors (GIST): analyses from INVICTUS. J Clin Oncol 38(15_suppl):11535–11535CrossRef
44.
Blay JY, Le Cesne A, Ray-Coquard I et al (2007) Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 25(9):1107–1113PubMedCrossRef
45.
Le Cesne A, Ray-Coquard I, Bui BN et al (2010) Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 11(10):942–949PubMedCrossRef
46.
Eichler M, Pink D, Menge F et al (2021) Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: cross-sectional results of a German multicentre observational study (PROSa). Eur J Cancer Care (Engl) 30(6):e13484PubMedCrossRef
Metadata
Title
The GIST of it all: management of gastrointestinal stromal tumors (GIST) from the first steps to tailored therapy. A bibliometric analysis
Authors
Julian Musa
Sarah M. Kochendoerfer
Franziska Willis
Christine Sauerteig
Jonathan M. Harnoss
Ingmar F. Rompen
Thomas G. P. Grünewald
Mohammed Al-Saeedi
Martin Schneider
Julian-C. Harnoss
Publication date
01-12-2024
Publisher
Springer Berlin Heidelberg
Published in
Langenbeck's Archives of Surgery / Issue 1/2024
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-024-03271-6

Other articles of this Issue 1/2024

Langenbeck's Archives of Surgery 1/2024 Go to the issue

Review

Technical variety of anastomotic techniques used in proximal gastrectomy with double-tract-reconstruction - a narrative review

Research

One-Anastomosis Gastric Bypass (OABG) vs. Single Anastomosis Duodeno-Ileal Bypass (SADI) as revisional procedure following Sleeve Gastrectomy: results of a multicenter study

Research

Laser speckle flowgraphy has comparable accuracy to indocyanine green fluorescence angiography in assessing bowel blood perfusion

Research

Proposal of set-up standardization for general surgery procedures with the CMR Versius system, a new robotic platform: our initial experience

Research

Incidence and clinical features of endometriosis in 2484 consecutive female patients undergoing appendectomy for suspected appendicitis—a retrospective analysis

Research

Enhanced recovery after surgery (ERAS) in colorectal surgery: implementation is still beneficial despite modern surgical and anesthetic care